Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes

MT Newswires Live

07/14

Pacific Edge (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.

The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.

Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.

In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.

The company's New Zealand shares gained 2% in recent Tuesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651405821"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651405821\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651405821?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 08:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651405821","market":"nz","top_or_hot":-1,"title":"Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.</p><p>The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.</p><p>Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.</p><p>In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, <a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> said.</p><p>The company's New Zealand shares gained 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacific Edge's APAC Business Progresses Toward Profitability on Higher Commercial Test Volumes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-14 08:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PFGTF\">Pacific Edge</a> (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.</p><p>The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.</p><p>Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.</p><p>In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, <a href=\"https://laohu8.com/S/PEB.AU\">Pacific Edge</a> said.</p><p>The company's New Zealand shares gained 2% in recent Tuesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651405821","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651405821","pubTimestamp":1783987753,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pacific Edge  said its Asia-Pacific  operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.The company's New Zealand shares gained 2% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PEB.AU":"PACIFIC EDGE LTD","PEB.NZ":"Pacific Edge Limited Ordinary Shares","BK8033":"生物科技","APAC":"Stonebridge Acquisition Corp"},"translate_title":"Pacific Edge 的 APAC 业务凭借更高的商业测试量实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEB.AU":1,"PEB.NZ":1.5,"APAC":1.5},"content_text":"Pacific Edge (ASX:PEB, NZE:PEB) said its Asia-Pacific (APAC) operations are progressing toward profitability on a direct-cost basis, supported by higher commercial test volumes and gaining adoption of the Cxbladder Triage Plus test, according to a Tuesday filing with the Australian and New Zealand bourses.The company said its APAC commercial test volume rose nearly 13% in the first quarter of fiscal year 2027 to 1,158 tests from 1,026 tests in the fourth quarter of fiscal year 2026.Meanwhile, APAC business revenue of NZ$2 million represented 19% of overall operating revenue in the second half of fiscal year 2026, up from 8% in fiscal 2025, the company said.In the US, commercial test volume fell 2.4% in the first quarter of fiscal year 2027 to 3,295 from 3,375 in the fourth quarter of fiscal year 2026 amid continuing attrition in the sales team, Pacific Edge said.The company's New Zealand shares gained 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}